



WORLD ECONOMIC FORUM



Technology
Pioneer
2007

NEWS RELEASE
FOR IMMEDIATE RELEASE

TSX Venture: AMF

AMORFIX RECEIVES ISO13485 CERTIFICATION
- Completes step toward commercialization of vCJD diagnostic test -

TORONTO, Ontario – June 15, 2007 – Amorfix Life Sciences (TSX-V:AMF), a company focused on diagnostics and treatments for brain wasting diseases, today announced that it has achieved ISO13485:2003 certification for its in vitro diagnostic EP-vCJD™ test for detection of aggregated misfolded proteins in variant Creutzfeldt-Jacob Disease (vCJD).

“This achievement is a significant step forward in the commercialization of our proprietary EP-vCJD™ diagnostic test for screening blood donations,” said Dr. George Adams, CEO of Amorfix Life Sciences. “The ISO certification demonstrates we have the processes needed to manufacture and distribute the test to the international quality standards required by customers. We are on schedule to obtain a European Union CE mark and launch our first product in the first quarter of 2008.”

ISO Certification

ISO13485:2003 is an internationally recognized process-based quality management system standard for medical devices developed by the International Organization for Standardization. ISO13485 specifies requirements for a Quality Management System which demonstrate the organization’s ability to provide medical devices and related services that consistently meet customer and applicable regulatory requirements. The management systems that are essential include staff training, customer and regulatory communication, product design and development, sourcing and purchasing of materials and services, and delivery of products and services.

About Amorfix

Amorfix is an emerging theranostics company focused on the diagnosis and treatment of brain-wasting diseases, where aggregated misfolded proteins (AMPs) are prevalent. These include “prions”, the infectious agents of the Transmissible Spongiform Encephalopathies (TSE), such as BSE and variant CJD, as well as degenerative diseases such as Alzheimer’s Disease, ALS and Parkinson’s Disease. Amorfix is focused on discovering and commercializing technologies to become the world leader on AMP diseases. The company will use this knowledge to develop diagnostic kits, treatments and vaccines for AMP diseases.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this

press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

- 30 -

For more information, please contact:

Dr. George Adams President & Chief Executive Officer Amorfix Life Sciences Ltd. Tel: (416) 482-3813 Fax: (416) 482-3811 george.adams@amorfix.com	James Parsons Chief Financial Officer Amorfix Life Sciences Ltd. Tel: (416) 482-3814 Fax: (416) 482-3811 james.parsons@amorfix.com
---	---